United States Patent 10,478,439: scope, claim-by-claim analysis, and US patent landscape for Compound 13 (BTK-directed oral regimen)
US 10,478,439 claims methods of treating human B‑cell proliferative disorders by oral administration of “Compound 13” defined chemically as 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with two linked exposure/PD anchors: AUC(0–24) > ~100 ng·h/mL and >90% BTK active-site occupancy in PBMCs at 24 hours, using a continuous once-daily regimen until progression or unacceptable toxicity. The dependent claims narrow to duration (≥6 months), hematologic malignancy types, and clinical subpopulations (prior bone marrow transplant, including autologous; relapsed/refractory disease).
What the claims cover in practice
- Drug: a specific stereospecific small molecule (“Compound 13”, (R)-configured).
- Route/dosing: oral, once daily, continuous treatment.
- PK/PD thresholds: AUC(0–24) > ~100 ng·h/mL and >90% BTK active-site occupancy in PBMCs at 24 hours.
- Indication class: “B‑cell proliferative disorder” including named NHL/CLL/MCL/FL/MZL/Waldenström/ABC-DLBCL selections.
- Clinical context: relapsed/refractory; prior bone marrow transplant, including autologous.
Hard infringement risk driver
In method patents like this, infringement turns on whether a commercial label or clinical protocol would practice the claimed regimen and whether the regimen achieves both the exposure and the BTK occupancy targets as claimed, not merely BTK inhibition in general.
What does US 10,478,439 actually claim: method of inhibiting proliferation and survival of activated B-cells using “Compound 13” with exposure and BTK occupancy thresholds?
Independent claim 1 is the anchor. It requires all elements:
- Patient: “human subject suffering from a B‑cell proliferative disorder”.
- Drug identity: oral administration of Compound 13 with a specific chemical structure and (R) configuration.
- Regimen: continuous once-daily regimen until progression or unacceptable toxicity.
- PK requirement: administration results in AUC(0–24) > about 100 ng·h/mL.
- PD requirement: administration results in >90% of BTK active sites in PBMCs occupied at 24 hours.
- Therapeutic effect: method is framed as inhibiting proliferation and survival of activated B‑cells.
Claim scope implications
- BTK occupancy is not optional. The claim explicitly requires quantified active-site occupancy (>90%) at 24 hours in PBMCs, so a product that does not reach that threshold at day 1 or thereafter may avoid the exact claim even if it is a BTK inhibitor.
- AUC is tied to a specific interval: AUC(0–24). If a sponsor supports an alternative exposure metric, or dose achieving similar trough binding but with AUC(0–24) not exceeding ~100 ng·h/mL, that can be a design-around vector.
- The regimen is “continuous” and “until progression/unacceptable toxicity.” That is broader than a fixed-duration protocol but narrower than “any administration” because it still requires the “continue until…” structure.
How broad are the “B-cell proliferative disorder” indications in US 10,478,439?
Claim 1 uses a broad category: B-cell proliferative disorder. Dependent claims then enumerate specific subsets.
Dependent claim coverage: hematologic malignancy mapping
- Claim 3: hematological malignancy.
- Claim 4: non-Hodgkin lymphoma (NHL).
- Claim 5: includes:
- chronic lymphocytic leukemia (CLL)
- small lymphocytic lymphoma (SLL)
- Waldenström’s macroglobulinemia (WM)
- Claim 6: includes:
- mantle cell lymphoma (MCL)
- follicular lymphoma (FL)
- marginal zone lymphoma (MZL)
- ABC-diffuse large B-cell lymphoma
Practical effect on enforcement
- If a defendant treats any labeled or studied disorder within these enumerated groups using the claimed PK/PD regimen, the case for practicing the method is stronger.
- If a defendant treats a B-cell disorder not listed in the dependents, the independent claim still covers it if it qualifies as a “B-cell proliferative disorder,” but proving infringement will depend on how the court interprets the term and whether prior art/arguments narrow interpretation.
What is the significance of the two quantitative thresholds (AUC(0–24) > ~100 ng·h/mL; >90% BTK occupancy at 24 hours)?
The thresholds convert a generic “BTK inhibitor” method patent into a PK/PD-defined dosing regimen.
How claim construction likely works
- AUC requirement: Must be satisfied by the dosing regimen that the defendant administers. In litigation, experts typically compare:
- measured PK in patients receiving the regimen, and/or
- model-predicted AUC(0–24) derived from administered dose and formulation.
- Occupancy requirement: Must be shown in PBMCs specifically, at 24 hours, and must exceed 90% of BTK active-site occupancy.
Infringement design-around vectors (claim-relevant)
- Lower exposure: avoid AUC(0–24) above the threshold (but this may risk loss of efficacy).
- Shift occupancy timing: maintain strong inhibition earlier but reduce occupancy at exactly 24 hours in PBMCs to below 90%.
- Different biomarker compartment: the claim keys off PBMCs. If a competitor targets a different measurement strategy, it does not automatically avoid infringement because PBMC occupancy can still be assessed, but it affects how easily plaintiffs can show proof.
How does claim 1’s “continuous once-daily regimen until progression or unacceptable toxicity” affect coverage?
This language matters for both:
- clinical protocol alignment and
- whether an episodic regimen could be argued not to practice the claim.
Dependent duration lock-in
- Claim 2: once daily regimen continued for at least 6 months.
So even if a competitor argues a shorter treatment course does not meet claim 2, claim 1 still captures continuation “until progression/unacceptable toxicity.” Claim 2 adds a minimum duration in a subset.
Which patient subgroups are added by the dependent claims? (bone marrow transplant; autologous transplant; relapsed/refractory)
Bone marrow transplant history
- Claim 7: prior bone marrow transplant.
- Claim 8: prior autologous bone marrow transplant.
This creates an enforcement “ladder”: the independent claim covers broad B‑cell proliferative disorders; the dependents add patient-history qualifiers that can be relevant in practice if the competitor’s intended label or real-world adoption targets those groups.
Disease status
- Claim 9: relapsed or refractory.
Dependent claims tie the same PK/PD and drug identity to disease state.
What does claim 10 add versus claim 1?
Claim 10 restates the method without the “until progression or unacceptable toxicity” formulation and instead emphasizes:
- the same drug,
- the same BTK occupancy threshold at 24 hours,
- and the therapeutic outcome (inhibiting proliferation and survival of activated B‑cells).
Notably, claim 10 does not include the AUC(0–24) > ~100 ng·h/mL limitation as written in your text. That makes claim 10 potentially broader on exposure and narrower on treatment-continuation language. In enforcement, claim 1 often provides the strongest PK+PD hook, while claim 10 can cover cases where AUC is disputed but occupancy is met.
How many claim “buckets” exist for infringement analysis? (independent + dependent structure)
Based on your claim text, there are at least four meaningful buckets:
- Independent PK+PD+continuous regimen bucket (claim 1): AUC threshold + occupancy threshold + continuous once-daily until progression/toxicity.
- Independent PD-only-ish bucket (claim 10): occupancy threshold + inhibition outcome (as written, without AUC and with less explicit “until progression/toxicity” language).
- Indication/disease-typing overlays: non-Hodgkin lymphoma; CLL/SLL/WM; MCL/FL/MZL/ABC-DLBCL.
- Patient-history overlays: prior BMT (autologous subset); relapsed/refractory; ≥6 months duration (claim 2).
For litigation, plaintiffs often test claim charts across the intersection of these buckets to establish which specific protocol elements were practiced.
What patents typically surround US 10,478,439 in the same compound family, and how does that affect freedom-to-operate risk?
A method claim like 10,478,439 commonly coexists with:
- compound claims (composition of matter) on the same active,
- formulation claims (controlled release, polymorphs, salts),
- intermediate/process claims (manufacturing),
- use claims (other dosing schedules, different PK targets),
- other PD target claims (occupancy at other times or in other cell types).
Scope interaction risk: even if a competitor avoids the exact PK/PD thresholds, it may still face composition-of-matter coverage or other method claims that are broader on thresholds or patient populations. Your provided prompt does not include the rest of the US patent family or related publications, so only the internal scope of 10,478,439 can be analyzed without introducing external factual claims.
What is the likely Orange Book status and FDA regulatory tie-in for US 10,478,439?
No FDA Orange Book listing or regulatory linkage information is provided in the prompt, and no specific marketed product name or NDA/BLA number for “Compound 13” is included. Without that, it is not possible to map 10,478,439 to:
- Orange Book drug code,
- listed patents,
- FDA label indications,
- or whether any listed patents are asserted in Paragraph IV actions.
(Therefore, this analysis focuses strictly on claim scope from the provided text.)
What generic or biosimilar risks exist specifically for a small-molecule method patent like 10,478,439?
If the active ingredient is a small molecule (it is chemically defined), the main competitive threat is a small-molecule generic with an approved bioequivalent dose regimen that may be alleged to practice the claimed method, depending on:
- whether the generic’s administered dosing achieves AUC(0–24) > ~100 ng·h/mL, and
- whether it achieves >90% BTK occupancy in PBMCs at 24 hours, and
- whether its intended use population matches the claim’s covered disorders and patient subgroups.
A “generic launch risk” is highest when:
- the generic label or clinical use matches the claimed indication language, and
- the generic dose/formulation is likely to generate comparable PK to the reference product that met the thresholds in the patent’s development.
How does the claims language shape litigation posture: what would plaintiffs and defendants focus on?
Plaintiff focus
- Show clinical PK that demonstrates AUC(0–24) > ~100 ng·h/mL for the relevant regimen (claim 1).
- Show pharmacodynamic data demonstrating >90% BTK active-site occupancy at 24 hours in PBMCs for the relevant regimen (claim 1 and claim 10).
- Tie the dosing regimen to the claim’s “method” and patient subset (NHL/CLL/WM/MCL/FL/MZL/ABC-DLBCL; relapsed/refractory; post-BMT; at least 6 months).
Defendant focus
- Challenge whether the defendant’s regimen truly meets both PK and PD thresholds (claim 1) or whether it meets only one (claim 10).
- Argue non-infringement based on:
- PK differences by formulation or dose,
- occupancy differences due to schedule, timing, or biomarker assay interpretation,
- patient population mismatch (if the defendant does not treat within enumerated disorders or patient-history overlays).
Could claim 10 broaden protection by dropping the AUC element?
As written in your text, yes. Claim 10:
- requires the occupancy threshold and therapeutic effect,
- but does not include the AUC(0–24) > ~100 ng·h/mL limit present in claim 1.
That means a competitor could avoid claim 1 by failing the AUC threshold, but still face risk under claim 10 if they hit the occupancy threshold and practice the method.
Key Takeaways
- US 10,478,439 is a dosing-and-biomarker method patent, not a generic “BTK inhibition” claim. It requires oral Compound 13 with once-daily continuous dosing and meets two quantitative constraints: AUC(0–24) > ~100 ng·h/mL and >90% BTK active-site occupancy in PBMCs at 24 hours (claim 1).
- Claim 10 appears broader on exposure (no AUC threshold in the provided text) but still hinges on >90% PBMC BTK occupancy at 24 hours.
- Indication coverage is anchored by dependent claims enumerating multiple B‑cell malignancies (CLL/SLL/WM; MCL/FL/MZL/ABC-DLBCL; and NHL framing).
- Patient-history and duration qualifiers (prior BMT including autologous; relapsed/refractory; ≥6 months) create narrower infringement lanes but do not limit the independent claim’s base coverage.
FAQs
1) Does US 10,478,439 require BTK inhibition as measured by PBMC active-site occupancy specifically at 24 hours?
Yes. The claims explicitly require >90% BTK active-site occupancy in PBMCs at 24 hours.
2) Can a competitor avoid infringement by using a different dosing interval than once-daily?
The claims require once-daily administration. A different interval is a core non-infringement argument because dosing schedule is an express limitation.
3) Does US 10,478,439 cover only continuous treatment until progression/unacceptable toxicity?
Claim 1 includes that language. Claim 10, as provided, removes the “until progression/unacceptable toxicity” phrasing, so coverage depends on which claim the asserted infringement theory targets.
4) Are specific lymphoma subtypes required to be treated to infringe?
Not for claim 1’s independent “B-cell proliferative disorder” category. Dependent claims list specific malignancies that can strengthen enforcement when the accused use maps to them.
5) Is the AUC threshold required for all asserted claims?
Based on your provided text, claim 1 includes AUC(0–24) > ~100 ng·h/mL, while claim 10 does not.
References (APA)
- United States Patent 10,478,439 (claims provided in prompt).
